Navigation Links
Experimental nonsteroidal treatment of asthma shows promise
Date:7/1/2010

A new nonsteroidal, anti-inflammatory therapy made from a human protein significantly decreases disease signs of asthma in mice, opening the possibility of a new asthma therapy for patients who do not respond to current steroid treatments. Results of this therapy in an animal model were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.

The protein, insulin-like growth factor binding protein-3 (IGFBP-3), uniquely inhibits specific physiological consequences of asthma examined in asthmatic mice, said Youngman Oh, PhD, a study co-author and a professor of pathology at Virginia Commonwealth University, Richmond, Virginia.

IGFBP-3 reportedly targets a key cellular pathway called nuclear factor kappa B, or NF-κB that plays a role in inflammation. The IGFBP-3 protein interferes with its cellular signaling and suppresses NF-κB activity.

"This novel mechanism has never been identified before. Our findings could have major implications not only for asthma but also other inflammatory diseases that NF-κB plays a role in, such as atherosclerosis and rheumatoid arthritis," Oh said.

In asthma, when the airways become inflamed, they become hyperreactive, or overly sensitive, to "triggers," such as dust, smoke and pet dander. This leads to a chain of reactions that elicit an asthma "attack". According to the American Lung Association nearly 23 million people have asthma, of which 9 million are children.

"Anti-inflammatory corticosteroid medicines are an important part of asthma management for many people, but an estimated 20 percent of patients with asthma are resistant to existing steroid medications and there is a critical need for alternate therapies," Oh said.

Using a mouse model, Oh and his colleagues showed that IGFBP-3 production is suppressed in asthma. They measured NF-κB inflammatory activity, using molecular and cellular techniques, and found that treatment with IGFBP-3 blocked NF-κB activity.

The researchers administered IGFBP-3 to the mice by spraying a synthetic form of the protein into their opened trachea. The treatment "reduced all physiological manifestations of asthma," including airway inflammation and hyperreactivity, Oh said. His research team plans to study IGFBP-3 treatment in asthmatic canine models next.


'/>"/>

Contact: Aaron Lohr
alohr@endo-society.org
240-482-1380
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Experimental stem cell treatment arrests acute lung injury in mice, study shows
2. Experimental Drug Offers Hope for Cystic Fibrosis Patients
3. Experimental Vaccine Shields Monkeys Against Ebola
4. Experimental targeted therapy shows early promise against medulloblastomas
5. Steroids May Be Overrated in Treatment of COPD
6. Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment
7. New study shows effectiveness of MEND program in prevention and treatment of pediatric obesity
8. New York City Surgeon Develops All-Natural Treatment for Wrinkles and Scars
9. Novelty lures rats from cocaine-paired settings, hinting at new treatments for recovering addicts
10. Northeast Chiropractic, PC Revolutionizes Pain Management Without Medication, Now Offering New and Unique Blend of Treatments
11. Autism-Supplements.com and Generation Rescue Work Together to Raise Money for Biomedical Autism Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... , ... June 27, 2016 ... ... the patient payment industry today announced its strategic partnership with Connance, a ... workflows. , The two companies’ proven, proprietary technology combine to provide health ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
Breaking Medicine Technology: